(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 14 February 2002 (14.02.2002)

PCT

(10) International Publication Number WO 02/11713 A2

(51) International Patent Classification⁷: A61K 31/00

(21) International Application Number: PCT/US01/24716

(22) International Filing Date: 6 August 2001 (06.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/633,389 7 August 2000 (07.08.2000) US

- (71) Applicant: ABBOTT LABORATORIES [US/US];
 D377 AP6D, 100 Abbott Park Road, Abbott Park, IL
 60064-6050 (US).
- (72) Inventors: JANUS, Todd, J.; 270 Big Terra Lane, Gurnee, IL 60031 (US). PADLEY, Robert, J.; 770 Moffett Road, Lake Bluff, IL 60044 (US).
- (74) Agents: STEELE, Gregory, W. et al.; Abbott Laboratories, 100 Abbott Park Road, D377 AP6D/2, Abbott Park, IL 60064-6050 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF TREATING CANCER AND THE PAIN ASSOCIATED THEREWITH USING ENDOTHELIN ANTAGONISTS



(57) Abstract: The instant invention is directed to methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.



Methods of Treating Cancer And The Pain Associated Therewith Using Endothelin Antagonists

5

10

15

20

Field of the Invention

The instant invention is directed to methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

Background of the Invention

Endothelin (ET), a 21 amino acid peptide, is produced by enzymatic cleavage of a precursor peptide by an endothelin converting enzyme. First discovered in vascular endothelial cells, ET and ET/ET receptor binding are now known to modulate smooth muscle tone, blood flow, cell proliferation and differentation, protein synthesis, and metabolic function in a variety of tissues and cell types such as ovary, prostate, skin, and brain.

2

ET/ET receptor binding has been shown to constrict arteries and veins; increase mean arterial blood pressure; decrease incardiac output; increase cardiac contractility in vitro; stimulate mitogenesis in vascular smooth muscle cells in vitro; contract non-vascular smooth muscle such as guinea pig trachea, human urinary bladder strips and rat uterus in vitro; increase airway resistance in vivo; induce formation of gastric ulcers; stimulate release of atrial natriuretic factor in vitro and in vivo; increase plasma levels of vasopressin, aldosterone, and catecholamines; inhibit release of renin in vitro; and stimulate release of gonadotropins in vitro.

10

15

20

ET/ET receptor binding also causes vasoconstriction on vascular smooth muscle (Nature 332 411 (1988), FEBS Letters 231 440 (1988) and Biochem. Biophys. Res. Commun. 154 868 (1988)). In fact, an anti-ET antibody has been shown to ameliorate adverse effects of renal ischemia on renal vascular resistance and glomerular filtration rate (J. Clin. Invest. 83 1762 (1989)). In addition, an anti-ET antibody attenuated both the nephrotoxic effects of intravenously administered cyclosporin (Kidney Int. 37 1487 (1990)) and the infarct size in a coronary artery ligation-induced myocardial infarction model (Nature 344 114 (1990)).

3

A nonpeptide ET antagonist prevents post-ischaemic renal vasoconstriction in rats, prevents the decrease in cerebral blood flow due to subarachnoid hemorrhage in rats, and decreases MAP in sodium-depleted squirrel monkeys when dosed orally (Nature 365: 759-761 (1993)). A similar effect of an ET antagonist on arterial calibera has also been recently reported (Biochem. Biophys. Res. Comm., 195: 969-75 (1993).

An ET receptor antagonist reduced injury in a rat model of colitis (EUR. J. Pharmacol. 1996, 309, 261-269) and prevented ischemia-reperfusion injury in kidney transplantation (Transplant Int 1996, 9, 201-207). The use of ET antagonists in the treatment of angina, pulmonary hypertension, Raynaud's disease, and migraine has also been suggested (Drugs 1996, 51,12-27). In malignant growth disorders, ET and its growth-promoting effects have been best characterized in prostate cancer, (Nature Medicine 1995, 1, 944-949) wherein ET acts as a modulator in osteoblastic bone lesion (UROLOGY 53:1063-1069, 1999).

10

15

Given the results from these and other reports which

illuminate the role of ET/ET receptor binding in disease

states, and the knowledge that blocking ET/ET receptor binding

results in improvement or reversal of endothelin-induced

4

disease states, agents which antagonize ET/ET receptor binding activity, designated as ET receptor antagonists, can provide substantial benefit in many therapeutic areas.

Summary of the Invention

5

10

15

20

In one embodiment of the instant invention, therefore, is disclosed a method for inhibiting bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

In another embodiment of the invention is disclosed a method for preventing new bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

In another embodiment of the instant invention, therefore, is disclosed a method for inhibiting metastatic growth in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

In another embodiment of the invention is disclosed a method for inhibiting bone loss in a patient which comprises

5

administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

In another embodiment of the instant invention, is disclosed a method for inhibiting bone turnover in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.

In another embodiment of the invention is disclosed a method for the reduction of cancer related pain in a patient in need thereof which comprises administering to the patient a therapeutically effective amount of an endothelin ET-A receptor antagonist.

10

15

In another embodiment of the instant invention is disclosed therapeutically acceptable formulations of an endothelin ET-A receptor antagonist, optionally in the presence of a co-therapeutic agent, for use in these methods.

Brief Description of the Drawings

Figure 1 illustrates levels of interleukin-6 (IL-6) in a subject population treated with a placebo or 2.5 mg or 10 mg ABT-627.

6

Figure 2 illustrates levels of prostate specific antigen (PSA) in a subject population treated with a placebo or 2.5 mg or 10 mg of ABT-627.

Figure 3 illustrates VAS score levels relating to pain assessment in a subject population treated with a placebo or 2.5 mg or 10 mg of ABT-627.

Figure 4 illustrates crosslinked N-telopeptides

10 (degradation) in a subject population treated with a placebo

or 10 mg ABT-627.

Figure 5 illustrates bone alkaline phosphatase (BAP) (formation) in a subject population treated with a placebo or 10 mg ABT-627.

15

Figure 6 illustrates skeletal involvement in a subject population treated with a placebo or 10 mg ABT-627.

Figure 7 illustrates acid phosphatase levels in a subject population treated with a placebo or 10 mg ABT-627.

7

Detailed Description of the Invention

Endothelin receptor antagonists are employed in the practice of the instant invention. Endothelins are a family of peptides mainly synthesized and released by endothelial cells. The term "endothelin" refers to a family of homologous 21-amino acid peptides found in 3 distinct isoforms: ET-1, ET-2, and ET-3.

5

10

15

20

The term "endothelin ET-A receptor antagonist" includes both compounds which antagonize the ET-A receptor in a selective manner, as well as compounds which antagonize the ET-A receptor in a non-selective manner. An example of the latter type of compound would be a compound that antagonizes the ET-A receptor and also antagonizes the ET-B receptor.

The term "primary cancer" means cancer in a specific tissue, which is first in time or in order of development. Primary cancers include, but are not limited to, breast, prostate, lung, kidney, thyroid, brain, heart, intestine, ovary, myeloma, lymphoma, sarcoma, and osteosarcoma.

The term "cancer-related pain" includes pain which arises from direct invasion or expansion of a tumor into tissue, such as bone or nerve; pain which arises from the consequences of tumor invasion or expansion, such as bone collapse due to

8

cancer erosion or secretion of noxious agents which modulate or produce pain; and pain mediated by ischemia, i.e. reduced blood flow.

Specifically, a compound of formula I may be employed in the practice of the instant invention

$$R_2$$
 Z
 R
 $(CH_2)_n$
 R_1

Ι

wherein

15

10 R is $-(CH_2)_m-W$;

Z is selected from $-C(R_{18})(R_{19})$ - and -C(O) -;

R₁ and R₂ are independently selected from hydrogen,
loweralkyl, alkenyl, alkynyl, alkoxyalkyl,
alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl,
alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl,
cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl,
dialkylaminocarbonylalkyl, aminocarbonylalkenyl,
alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl,
hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl,

9

arylalkoxyalkyl, (N-alkanoyl-N-alkyl) aminoalkyl, alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic) alkyl, and $(R_{aa})(R_{bb})N-R_{cc}$,

with the proviso that one or both of R_1 and R_2 is other than hydrogen;

R₃ is selected from R₄-C(O)-R₅-, R₄-R_{5a}-, R₄-C(O)-R₅N(R₆)-, R₆-S(O)₂-R₇- R₂₆-S(O)-R₂₇-, R₂₂-O-C(O)-R₂₃-,
loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
aryl, arylalkyl, aryloxyalkyl, heterocyclic,

(heterocyclic)alkyl, alkoxyalkyl, alkoxyalkyl, and R₁₃- C(0)-CH(R₁₄)-;

R4 and R6 are independently selected from (R11)(R12)N-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and

$$(CH_2)_z$$
 N R_{7a} R_{7a}

15

R5 is selected from a covalent bond, alkylene,

10

alkenylene, $-N(R_{20})-R_8-$, $-R_{8a}-N(R_{20})-R_8-$, $-O-R_9-$, and $-R_{9a}-O-R_9-$;

R₆ is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R7 is a covalent bond, alkylene, alkenylene $-N(R_{21})-R_{10-}$, and $-R_{10a}-N(R_{21})-R_{10-}$;

R₈ is selected from alkylene and alkenylene;

R9 is alkylene;

5

R₁₀ is selected from alkylene and alkenylene;

10 R₁₁ and R₁₂ are independently selected from hydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl,trialkylaminoalkyl, alkylaminoalkyl,

15 dialkylaminoalkyl, and carboxyalkyl;

R13 is selected from amino, alkylamino and dialkylamino;

R₁₄ is selected from aryl and R₁₅-C(O)-;

R₁₅ is selected from amino, alkylamino and dialkylamino;

R16 is selected from loweralkyl, haloalkyl, aryl and

20 dialkylamino;

R₁₇ is loweralkyl;

11

 R_{18} and R_{19} are independently selected from hydrogen and loweralkyl;

R20 is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cylcoalkyl and cycloalkylalkyl;

R₂₁ is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, aryl and arylalkyl;

 R_{22} is selected from a carboxy protecting group and heterocyclic;

10 R_{23} is selected from covalent bond, alkylene, alkenylene and $-N(R_{24})-R_{25}-;$

 R_{24} is selected from hydrogen and loweralkyl;

R₂₅ is alkylene;

5

R26 is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxysubstituted haloalkyl;

R27 is selected from alkylene and alkenylene;

R5a is selected from alkylene and alkenylene;

20 R_{7a} is alkylene;

R_{8a} is selected from alkylene and alkenylene;

R_{9a} is alkylene;

R_{10a} is selected from alkylene and alkenylene;

R_{aa} is selected from aryl and arylalkyl;

Rbb is selected from hydrogen and alkanoyl;

R_{CC} is alkylene;

m is 0-6;

5

10

15

n is 0 or 1;

z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from $-C(O)_2-G$; $-PO_3H_2$, -P(O)(OH)(E), $-CN, -C(O)NHR_{17}, alkylaminocarbonyl, dialkylaminocarbonyl,$ tetrazolyl, hydroxy, alkoxy, sulfonamido, $-C(O)NHS(O)_2R_{16}$, $-S(O)_2NHC(O)R_{16}$,

13

or a pharmaceutically acceptable salt thereof.

5

10

15

A preferred embodiment of the a compound of formula I is a compound of formula II

$$R_{2} \xrightarrow{Z} N R_{3}$$

$$|CH_{2}|_{n}$$

$$|R_{1}|$$

II

wherein the substituents $-R_2$, -R and $-R_1$ exist in a trans, trans relationship and Z, n, R, R₁, R₂, and R₃ are as defined above.

Compounds of formulas I and II are endothelin antagonists, specifically ${\rm ET}_{\scriptscriptstyle A}{\rm -selective}$ endothelin antagonists.

Another preferred embodiment of the invention is a compound of formula I or II wherein n is 0 and Z is $-\mathrm{CH}_2-.$

Another preferred embodiment of the invention is a compound of formula I or II wherein n is 1 and Z is $-\text{CH}_2-$.

Another preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, and R₃

14

is R₄-C(O)-R₅- , R₆-S(O)₂-R₇- or R₂₆-S(O)-R₂₇- wherein R₄, R₅, R₆, R₇, R₂₆ and R₂₇ are as defined above.

Another preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH $_2$ -, and R $_3$ is alkoxyalkyl or alkoxyalkoxyalkyl.

5

10

20

A more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, and R₃ is R₄-C(0)-R₅- wherein R₄ is $(R_{11})(R_{12})N$ - as defined above and R₅ is alkylene or R₃ is R₆-S(0)₂-R₇- or R₂₆-S(0)-R₂₇- wherein R₇ is alkylene, R₂₇ is alkylene and R₆ and R₂₆ are defined as above.

Another more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is $-CH_2- \ and \ R_3 \ is \ R_4-C(O)-N(R_{2\,O})-R_8- \ or$

R₆-S(O)₂-N(R₂₁)-R₁₀- wherein R₈ and R₁₀ are alkylene and R₄, R₆, R₂₀ and R₂₁ are defined as above.

An even more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is tetrazolyl or $-C(0)_2$ -G wherein G is hydrogen or a carboxy protecting group or R is tetrazolyl or R is $-C(0)_2$ R₁₆ wherein R₁₆ is loweralkyl, haloalkyl or aryl,

15

Z is -CH₂-; R₁ and R₂ are independently selected from (i) loweralkyl, (ii) cycloalkyl, (iii) substituted aryl wherein aryl is phenyl substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, halo, alkoxyalkoxy and carboxyalkoxy, (iv) substituted or 5 unsubstituted heterocyclic, (v) alkenyl, (vi) heterocyclic (alkyl), (vii) arylalkyl, (viii) aryloxyalkyl, (ix) (Nalkanoyl-N-alkyl) aminoalkyl and (x) alkylsulfonylamidoalkyl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is $(R_{11})(R_{12})N$ - wherein R_{11} and R₁₂ are independently selected from loweralkyl, haloalkyl, 10 alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, and trialkylaminoalkyl, and R_5 is alkylene; or R_3 is $R_4-C(0)-N(R_{20})-R_8-$ or $R_6-S(0)_2-$ N(R₂₁)-R₁₀- wherein R₄ is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and R6 is loweralkyl, 15 haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl, R8 and R₁₀ are alkylene and R₂₀ and R₂₁ are loweralkyl; or R₃ is $R_6-S(0)_2-R_7-$ or $R_{26}-S(0)-R_{27}-$ wherein R_6 is loweralkyl or haloalkyl, R7 is alkylene, R26 is loweralkyl and R27 is alkylene. 20

A yet more preferred embodiment of the invention is a

16

compound of formula I or II wherein n is 0, R is $-C(0)_2-G$ wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(O)-NHS(O) $_2$ R $_{16}$ wherein R $_{16}$ is loweralkyl, haloalkyl or aryl, Z is -CH2-, R1 is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) pyridyl, (vii) furanyl, (viii) substituted or unsubstituted 4methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4-10 hydroxyphenyl, 4-t-butylphenyl, 1,3-benzodioxolyl, 1,4benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) heterocyclic (alkyl), (x) arylalkyl, (xi) aryloxyalkyl, (xii) 15 (N-alkanoyl-N-alkyl) aminoalkyl, or (xiii) alkylsulfonylamidoalkyl, R_2 is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofurnayl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and R_3 is R_4 -20 $C(0)-N(R_{20})-R_{8}-$ or

17

 R_6 -S(O)₂-N(R_{21})- R_{10} - wherein R_8 and R_{10} are alkylene, R_{20} and R_{21} are loweralkyl, R_4 is loweralkyl, aryl, alkoxy, alkylamino, aryloxy or arylalkoxy and R_6 is loweralkyl, haloalkyl, alkoxyalkyl, aryl or arylalkyl.

Another yet more preferred embodiment of the invention is 5 a compound of formula I or II wherein n is 0, R is -C(O)2-G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(0)-NHS(0)₂R₁₆ wherein R₁₆ is loweralkyl, haloalkyl or aryl, Z is -CH2-, R1 is (i) loweralkyl, (ii) alkenyl, (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi) 10 pyridyl, (vii) furanyl, (viii) substituted or unsubstituted 4methoxyphenyl, 4-fluorophenyl, 3-fluorophenyl, 4-ethoxyphenyl, 4-ethylphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4pentafluoroethylphenyl, 3-fluoro-4-methoxyphenyl, 3-fluoro-4-15 ethoxyphenyl, 2-fluorophenyl, 4-methoxymethoxyphenyl, 4hydroxyphenyl, 4-t-butylphenyl, 1,3-benzodioxolyl, 1,4benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, (ix) heterocyclic (alkyl), (x) arylalkyl, (xi) aryloxyalkyl, (xii) (N-alkanoyl-N-alkyl) aminoalkyl, or (xiii) 20 alkylsulfonylamidoalkyl, R2 is substituted or unsubstituted

18

1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofurnayl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and R3 is R4-C(0)-R5- wherein R5 is alkylene and R4 is (R11)(R12)N- wherein R_{11} and R_{12} are independently selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heterocyclic, hydroxyalkyl, alkoxy, aminoalkyl, and trialkylaminoalkyl.

5

Another yet more preferred embodiment of the invention is 10 a compound of formula I or II wherein n is 0, R is $-C(0)_2-G$ wherein G is hydrogen or a carboxy protecting group, tetrazolyl or $-C(0)-NHS(0)_2R_{16}$ wherein R_{16} is loweralkyl, haloalkyl or aryl, Z is -CH₂-, R₁ is (i) loweralkyl, (ii) alkenyl, (iii) heterocyclic(alkyl), (iv) aryloxyalkyl, (v) 15 arylalkyl, (vi) aryl, (vii) (N-alkanoyl-N-alkyl)aminoalkyl, or (viii) alkylsulfonylamidoalkyl, R2 is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, benzofurnayl, 4-methoxyphenyl, 20

dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the

19

substituent is selected from loweralkyl, alkoxy and halogen and R_3 is R_4 -C(0)- R_5 - wherein R_5 is alkylene and R_4 is $(R_{11})(R_{12})N$ - wherein R_{11} is loweralkyl and R_{12} is aryl, arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, or heterocyclic.

5

Another yet more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(O)2-G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(0) -NHS(0)₂R₁₆ wherein R₁₆ is loweralkyl, haloalkyl or aryl, Z is -CH2-, R1 is (i) loweralkyl, (ii) 10 alkenyl, (iii) heterocyclic (alkyl), (iv) aryloxyalkyl, (v) arylalkyl, (vi) (N-alkanoyl-N-alkyl)aminoalkyl, or (vii) alkylsulfonylamidoalkyl, (vii) phenyl, or (ix) substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-15 fluorophenyl, 3-fluoro-4-ethoxyphenyl, 2-fluorophenyl, 4methoxymethoxyphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, R₂ is substituted or unsubstituted 1,3-benzodioxolyl, 7methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-20 benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl,

20

dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and R_3 is R_6 -S(O)₂-N(R_{21})- R_{10} - wherein R_{10} is alkylene, R_6 is loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl and R_{21} is loweralkyl, haloalkyl, alkoxyalkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl.

Another yet more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is $-C(0)_2-G$ wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(0)-NHS(0)₂R₁₆ wherein R₁₆ is loweralkyl, 10 haloalkyl or aryl, Z is -CH2-, R1 is (i) substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-benzodioxolyl or 1,4-benzodioxanyl wherein the substituent is selected from loweralkyl, haloalkyl, alkoxy and 15 alkoxyalkoxy, (ii) loweralkyl, (iii) alkenyl, (iv) heterocyclic (alkyl), (v) aryloxyalkyl, (vi) arylalkyl, (vii) (N-alkanoyl-N-alkyl) aminoalkyl, (viii) alkylsulfonylamidoalkyl, or (ix) phenyl, R2 is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 20 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl,

21

dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and R_3 is alkoxycarbonyl or R_6 -S(O)₂-N(R_{21})- R_{10} - wherein R_{10} is alkylene, R_6 is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl and R_{21} is loweralkyl, haloalkyl, alkoxyalkyl or haloalkoxyalkyl.

5

10

15

Another yet more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is $-C(0)_2$ -G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(0)-NHS(0) $_2$ R $_{16}$ wherein R $_{16}$ is loweralkyl or haloalkyl, Z is $-CH_2$ -, R $_1$ is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and R $_3$ is R $_4$ -C(0)-R $_5$ - wherein R $_5$ is alkylene and R $_4$ is (R $_{11}$)(R $_{12}$)N- wherein R $_{11}$ and R $_{12}$ are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic.

A still more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is $-C(0)_2$ -G wherein G is hydrogen or a carboxy protecting group,

22

tetrazolyl or -C(0)-NHS(0) $_2$ R $_{16}$ wherein R $_{16}$ is loweralkyl or haloalkyl, Z is -CH2-, R1 is substituted or unsubstituted 4methoxyphenyl, 4-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-5 benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, (ii) loweralkyl, (iii) alkenyl, (iv) heterocyclic (alkyl), (v) aryloxyalkyl, (vi) arylalkyl, (vii) (N-alkanoyl-N-alkyl) aminoalkyl, (viii) 10 alkylsulfonylamidoalkyl,or (ix) phenyl, R2 is 1,3benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and R₃ is R₄-C(O)-R₅- wherein R₅ is alkylene and R_4 is $(R_{11})(R_{12})N$ - wherein R_{11} and R_{12} are independently 15 selected from loweralkyl, aryl, arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, or heterocyclic.

Another still more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is $-C(0)_2$ -G wherein G is hydrogen or a carboxy protecting group, tetrazolyl or -C(0)-NHS(0) $_2$ R $_{16}$ wherein R $_{16}$ is loweralkyl or

23

haloalkyl, Z is -CH₂-, R₁ is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, arylalkyl, (N-alkanoyl-N-alkyl)aminoalkyl, alkylsulfonylamidoalkyl, phenyl, or alkoxyalkyl, R₂ is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and R₃ is R₄-C(O)-R₅- wherein R₅ is alkylene and R₄ is (R₁₁) (R₁₂)N- wherein R₁₁ and R₁₂ are independently selected from loweralkyl, aryl, arylalkyl, hydroxyalkyl, alkoxy, aminoalkyl,

A most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(0)₂-G wherein G is hydrogen or a carboxy protecting group, Z is -CH₂-, R₁ is substituted or unsubstituted 4-methoxyphenyl, 4- fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4- trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, R₂ is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl,

trialkylaminoalkyl, or heterocyclic.

10

24

dimethoxyphenyl, fluorophenyl or difluorophenyl and R $_3$ is R $_4$ -C(0)-R $_5$ - wherein R $_5$ is alkylene and R $_4$ is (R $_{11}$)(R $_{12}$)N- wherein R $_{11}$ and R $_{12}$ are independently selected from loweralkyl.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(O)2-G 5 wherein G is hydrogen or a carboxy protecting group, Z is -CH2-, R1 is substituted or unsubstituted 4-methoxyphenyl, 4fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 4trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4methoxymethoxyphenyl, 4-hydroxyphenyl, 4-ethylphenyl, 1,3-10 benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from alkoxy, alkoxyalkoxy and carboxyalkoxy, R2 is 1,3-benzodioxolyl, 1,4-benzodioxanyl, dihydrobenzofuranyl, benzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl and R3 is R4-15 $C(0)-R_5-$ wherein R_5 is alkylene and R_4 is $(R_{11})(R_{12})N-$ wherein R_{11} is loweralkyl and R_{12} is aryl.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(0)₂-G

wherein G is hydrogen or a carboxy protecting group, Z is
CH₂-, R₁ is substituted or unsubstituted 4-methoxyphenyl, 3-

25

fluoro-4-methoxyphenyl, 3-fluorophenyl, 2-fluorophenyl, 3fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl
wherein the substituent is selected from loweralkyl,

haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, R₂ is
substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl,
dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl,
fluorophenyl or difluorophenyl wherein the substituent is
selected from loweralkyl, alkoxy and halogen and R₃ is R₆S(O)₂-N(R₂₁)-R₁₀- wherein R₁₀ is alkylene, R₆ is loweralkyl,
haloalkyl, alkoxyalkyl or haloalkoxyalkyl and R₂₁ is
loweralkyl, haloalkyl or alkoxyalkyl.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(0)₂-G wherein G is hydrogen or a carboxy protecting group, Z is -CH₂-, R₁ is substituted or unsubstituted 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-fluorophenyl, 2-fluorophenyl, 3-fluoro-4-ethoxyphenyl, 4-methoxymethoxyphenyl, 1,3-° benzodioxolyl, 1,4-benzodioxanyl or dihydrobenzofuranyl wherein the substituent is selected from loweralkyl,

26

haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy, R_2 is substituted or unsubstituted 1,3-benzodioxolyl, 7-methoxy-1,3-benzodioxolyl, 1,4-benzodioxanyl, 8-methoxy-1,4-benzodioxanyl, dihydrobenzofuranyl, 4-methoxyphenyl, dimethoxyphenyl, fluorophenyl or difluorophenyl wherein the substituent is selected from loweralkyl, alkoxy and halogen and R_3 is R_4 - C(O)- R_5 - wherein R_5 is alkylene and R_4 is (R_{11}) (R_{12}) N- wherein R_{11} is alkyl and R_{12} is selected from aryl, aminoalkyl,

5

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(0)₂-G wherein G is hydrogen or a carboxy protecting group, Z is -CH₂-, R₁ is loweralkyl, alkenyl, heterocyclic (alkyl), aryloxyalkyl, aryalkyl, aryl, (N-alkanoyl-N-alkyl)aminoalkyl, or alkylsulfonylamidoalkyl, and R₃ is R₄-C(0)-R₅- wherein R₅ is alkylene and R₄ is (R₁₁)(R₁₂)N- wherein R₁₁ and R₁₂ are independently selected from alkyl, aryl, hydroxyalkyl, alkoxy, aminoalkyl, trialkylaminoalkyl, and heterocyclic, with the proviso that one or R₁₁ and R₁₂ is alkyl.

trialkylaminoalkyl, and heterocyclic.

20 Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-,

27

and R₃ is R₄-C(O)-R₅- wherein R₄ is $(R_{11})(R_{12})N$ - as defined therein and R₅ is alkylene.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is loweralkyl, and R_3 is R_4 -C(O)- R_5 - wherein R_4 is (R_{11}) (R_{12}) N- as defined therein and R_5 is alkylene.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is alkenyl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is R_{11} (R_{12})N- as defined therein and R_5 is alkylene.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is heterocyclic (alkyl), and R_3 is

 R_4 -C(O)- R_5 - wherein R_4 is $(R_{11})(R_{12})N$ - as defined therein and . R_5 is alkylene.

10

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is aryloxyalkyl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is (R_{11}) (R_{12}) N- as defined therein and R_5 is alkylene.

20 Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-,

28

 R_1 is arylalkyl, and R_3 is R_4 -C(O)- R_5 - wherein R_4 is (R_{11}) (R_{12}) N- as defined therein and R_5 is alkylene.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is aryl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is (R_{11}) (R_{12}) N-as defined therein and R_5 is alkylene.

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is (N-alkanoyl-N-alkyl)aminoalkyl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is (R_{11}) (R_{12}) N- as defined therein and R_5 is alkylene.

10

15

Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH₂-, R_1 is alkylsulfonylamidoalkyl, and R_3 is R_4 -C(0)- R_5 - wherein R_4 is $(R_{11})(R_{12})N$ - as defined therein and R_5 is alkylene.

A particularly preferred compound of formula I is a compound of formula III, also known as ABT-627:

29

III

compounds of formula I, II, and III may be synthesized by methods provided in commonly owned U.S. patent application Serial No. 09/048,955, filed March 27, 1998, U.S. patent application Serial No. 08/794,506, filed February 4, 1997, U.S. patent application Serial No. 08/600,625, filed February 13, 1996, U.S. patent application Serial No. 08/497,998, filed August 2, 1995, U.S. patent application Serial No. 08/442,575, filed May 30, 1995, U.S. patent application Serial No. 08/334,717, filed November 4, 1994, and U.S. patent application Serial No. 08/334,717, filed November 4, 1994, and U.S. patent application Serial No. 08/293,349, filed August 19, 1994, the disclosures of which are herein incorporated by reference.

Other suitable endothelin ET-A receptor antagonist may

15

30

be used, such as those disclosed in U.S. Patent Nos. 6,048,893, 6,017,951, and 5,998,468.

5

10

15

The term "inhibit" is defined to include its generally accepted meaning which includes preventing, prohibiting, restraining, and slowing, stopping or reversing progression, or severity, and holding in check and/or treating existing characteristics. The present method includes both medical therapeutic and/or prophylactic treatment, as appropriate.

The methods of the present invention are useful in men as well as in women. Preferably, however, the methods of the present invention are useful in men, more preferably men with prostate cancer.

The ability of the compounds of formula I, II, and III to treat cancers can be demonstrated according to the method described in J. Clin. Invest. <u>87</u> 1867 (1991). Types of cancer includes primary cancer such as breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.

The ability of the compounds of the invention to treat of nociception can be demonstrated according to the method described in J. Pharmacol. Exp. Therap. 271 156 (1994).

The compounds of the present invention can be used in the

31

form of salts derived from inorganic or organic acids. salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, 5 dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, 10 pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, ptoluenesulfonate and undecanoate. Also, the basic nitrogencontaining groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl 15 chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or 20

Examples of acids which may be employed to form

dispersible products are thereby obtained.

32

pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

5

10

15

20

Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of formula I, or separately by reacting the carboxylic acid function with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary Such pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

The compounds of formulas I, II and III are useful for

33

antagonizing endothelin in humans or other mammals. Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 1000 mg/kg body weight daily and more usually 0.1 to 100 mg/kg for oral administeration or 0.01 to 10 mg/kg for parenteral administeration. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

Pharmaceutical formulations may be prepared by procedures known in the art. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administeration.

10

15

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administeration, route of administeration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.

The compounds of the present invention may be administered orally, buccally, parenterally, sublingually, by inhalation spray, rectally, or topically in dosage unit

formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.

Topical administeration may also involve the use of transdermal administeration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, transcutaneous, intradermal, or infusion techniques.

Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic monoor diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

35

Suppositories for rectal administeration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administeration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

10

15

20

Liquid dosage forms for oral administeration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

36

The compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic.

5

10

15

20

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

A representative solid dosage form, for example, a tablet or a capsule, comprises:

Compound of the invention: 35% w/w

Starch, Pregelatinized, NF 50% w/w

Microcrystalline Cellulose, NF 10% w/w

Talc, Powder, USP 5% w/w

While the compounds of the invention can be administered

37

5

10

15

20

as the sole active therapeutic agent, they can also be used in combination with one or more co-therapeutic agents, such as anticancer drugs or methods including, but not limited to, hormonal agents, such as leuprolide (Lupron®); gonadorelin antagonists, such as goserelin (Zoladex®) and abarelix; bicalutamide; nilutamide; flutamide; vitamin D; vitamin D analogues; estrogen and estrogen analogues, such as diethylstibestrol; prednisone; hydrocortisone; ketoconazole; cyproterone acetate; progesterone; 5-alpha reductase inhibitors, such as finasteride; bone-seeking radionuclides, such as samarium (Quadramet[®]), strontium (Metastron[®]), and 186 rhenium; external beam radiation, including three dimensional conformal radiation; brachytherapy, which is the implantation of radioactive seeds directly into the prostate; monoclonal antibodies such as trastuzumab (Herceptin®); antiangiogenic agents such as thrombospondin peptide or kringle 5; matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; lycopenes; urokinase; plasminogen activator inhibitors; plasminogen activator receptor blockers; apoptosis inducers; selective and non-selective alpha blockers; platinum agents, such as cis-platinum and carbo-platinum; taxane class agents, such as docitaxil and paclitaxil; estramustine;

38

gemcytabine; adriamycin; doxorubicin; daunorubicin;
mitoxantrone; vinblastine; vincristine; capecitabine;
irinotecan; topotecan;

5-fluorouracil; interferons; cytoxan; methotrexate; cytokines, such as IL-2; PPAR agonists, such as thiazolidine diones; retinoid-type agents, 5-lipooxygenase inhibitors, such as zyfo (Zilueton*), COX-2 inhibitors; gene-therapy based therapeutics, including sense and anti-sense genes; cholesterol lowering drugs, such as lovastatin, pravastatin, and simvistatin; bisphosphonates; osteoprotegrin; and antibodies, both monoclonal and polyclonal; antibody-coupled radionucleotides; antibody-coupled cytotoxic agents; antibody-coupled radionucleotides; viral-vector delivered agents; vaccines directed at protein, carbohydrate, or nucleic acid targets; aminoglutethimide; and suramin.

10

15

20

These combinations can be administered as separate compositions or as a single dosage form containing both or all agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions, which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

In addition, the compounds invention can be used in

39

combination with one or more co-therapeutic agents which impede net bone loss, such as estrogens, bisphosphonates, and estrogen receptor modulators, such as raloxifene, and calcitonin.

The compounds of the invention can additionally be administered in combination with surgery, such as radical prostatectomy, cryotherapy, transurethral resection of the prostate as an adjuvant, and the like, or prior to surgery as a neoadjuvant agent.

5

10

15

20

The current major diseases or conditions of bone which are of public concern include, but are not limited to, post-menopausal osteoporosis, ovariectomy patients, senile osteoporosis, patients undergoing long-term treatment of corticosteroids, side effects from glucocorticoid or steroid treatment, patients suffering from Cushings's syndrome, gonadal dysgenesis, periarticular erosions in rheumatoid arthritis, osteoarthritis, Paget's disease, osteohalisteresis, osteomalacia, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, osteroperosis from Lupron therapy, and starvation. All of these conditions are characterized by bone loss, resulting from an imbalance between the degradation of bone (bone

40

resorption) and the formation of new healthy bone. This turnover of bone continues normally throughout life and is the mechanism by which bone regenerates. However, the conditions stated above will tip the balance towards bone loss such that the amount of bone resorbed is inadequately replaced with new bone, resulting in net bone loss.

5

10

15

20

Examples

Studies were performed on male subjects with asymptomatic hormone refractory prostate cancer with rising PSA levels and on male subjects with symptomatic hormone refractory prostate cancer with rising PSA levels and pain. Subjects in the phase II studies had castrate levels of testosterone, either due to pharmacologic intervention, via leuprolide (Lupron®) or goserelin (Zoladex®), or via surgical castration. Subjects received ABT-627 or placebo. The following tests were conducted:

ABT-627 was formulated in 2.5 and 10 mg doses. An oral liquid formulation of ABT-627 was also prepared as follows: 1 mg/ml ABT-627, 50% glycerin, 14% alcohol, and water. Matching placebos were also provided.

A number of recognized or putative biochemical markers of

41

disease progression have been used to monitor treatment of individuals with prostate cancer. Among these markers are serum Prostate Specific Antigen (PSA), serum acid Phosphatase, Interleukin-6, and Chromagranin-A. As currently accepted, favorable treatment is marked by a decrease or slower rate of increase for PSA, acid phosphatase, and Interleukin-6, while a favorable response is marked by an increase in Chromagranin-A.

Serum samples were obtained from subjects during treatment with the ET antagonist ABT-627 in order to determine PSA, acid phosphatase, IL-6, and Chromagranin-A values.

10

15

20

Prostate Specific Antigen Level Assay

The effect of ABT-627 administeration on prostate specific antigen (PSA) levels in human subject serum samples was determined using the procedure described in the Chiron Diagnostics ACS: Centaur PSA2 Assay. This assay is a two-site sandwich immunoassay which uses direct chemiluminescense and constant amounts of two antibodies. The first antibody, the Lite Reagent, is an affinity purified polyclonal sheep anti-PSA antibody labeled with acridinium ester. The Lite Reagent is purchased as a 5.0 mL reagent pack comprising the polyclonal sheep anti-PSA antibody sheep anti-PSA antibody (3.1 µg) in buffered saline

42

with sodium azide (0.1%). The second antibody, the Solid Phase, is a monoclonal mouse anti-PSA antibody covalently coupled to paramagnetic particles. The Solid Phase is purchased as a 25.0 mL reagent pack comprising the covalently coupled monoclonal mouse anti-PSA antibody (316 µg) in buffered saline with sodium azide (0.1%). The assay was performed at Quintiles Laboratories (Smyrna, GA) using Chiron Diagnostics ACS: Centaur® Automated Chemiluminescence Systems.

10

15

20

Briefly, a subject population was treated with a placebo or 2.5 mg or 10 mg of ABT-627. Blood samples were collected, allowed to adequately clot, centrifuged at 1000 x g for 15-20 minutes, and stored at -20 °C if not assayed within 48 hours. A cuvette was charged sequentially with serum, Lite Reagent (50 µL), and Solid Phase (250 µL). The resulting mixture was incubated for 7.5 minutes at 37 °C, separated, and treated with the solution of Acid Reagent and Base Reagent to initiate the chemiluminescent reaction. A direct relationship exists between the amount of PSA present in the patient sample and the RLU's (relative light units) detected. As shown by the area under the curve (AUC) in Figure 2, the rate of increase of PSA in the serum samples decreases after the adminsteration of ABT-627, demonstrating the effectivness of ABT-627 as an

43

agent for treating prostate cancer.

10

15

20

Acid Phosphatase Levels

The effect of ABT-627 administeration on Acid Phosphatase levels in human subject serum samples was determined at Quintiles Laboratories using the chemical test described in Sigma Diagnostics Acid Phosphatase (ACP) Procedure No. 435.

The enzyme Acid Phosphatase (ACP) catalyzes the hydrolysis of alpha-naphthyl phosphate to alpha-naphthol and inorganic phosphate. The alpha-naphthol immediately reacts with fast red TR salt to produce a yellow chromophore with an absorbance maximum at 405 nm. The rate of increase in absorbance at 405 nm is directly proportional to ACP activity in the sample.

ACP activity was determined in the presence and absence of L-tartrate, the difference being attributed to prostatic acid phosphatase activity.

Briefly, a subject population was treated with a placebo or 2.5 mg or 10 mg of ABT-627. Blood samples were collected, allowed to adequately clot, centrifuged at 1000 x g for 15-20 minutes, and stored at -20 °C if not assayed within 48 hours. Assays were performed on a Hitachi Spectrophotomer. A cuvette was charged sequentially with ACP reagent (1 mL), prepared as

44

described in the assay protocol, and serum (0.1 mL). The mixture was agitated and incubated for 5 minutes, and an absorbance (A) at 405 nm (versus water as a reference) was read to provide an initial absorbance. The mixture was incubated for another 5 minutes, and a second absorbance was read to provide a final absorbance. A change A/5 minute value was obtained by subtracting the initial absorbance from the final absorbance and was used to calculate total ACP activity.

To provide the tartrate-resistant acid phosphatase activity, the above procedure was repeated with the addition of ACP tartrate reagent (0.01 mL) to the cuvette containing the ACP reagent and mixing before adding the serum. Prostatic acid phosphatase activity was calculated by subtracting the the tartrate-resistant acid phosphatase activity from the ACP activity. As shown shown by the (AUC) in Figure 7, the rate of increase and the average change from baseline for acid phosphatase was decreased in those subjects treated with ABT-627, again demonstrating the effectivness of ABT-627 as an agent for treating prostate cancer.

20

10

45

The effect of ABT-627 adminstration on Chromagranin-A levels in human serum samples was determined by proprietary assay conducted at the Nichols Institute. The procedure is a two site chemiluminescence assay (ICMA) using one monoclonal antibody conjugated with biotin, another monoclonal antibody labeled with an acridinium ester, and an avidin-coated solid phase. The antibody/Chromagranin-A/antibody complex is bound to the solid phase by the avidin-biotin interaction and unbound materials are removed by washing. The bound, acridinium-labeled material produces light that is detected in a luminometer after addition of triggering agents. The Limit of Detection (LOD) for the assay was 0.07 ng/mL. As shown by the AUC in Figure 8, the average change from baseline for Chromagranin-A was higher for subjects treated with 2.5 mg/day of ABT-627, again demonstrating the effectivness of ABT-627 as an agent for treating prostate cancer.

5

10

15

Interleukin-6 Levels

The effect of ABT-627 adminstration on Interleukin-6

levels in human serum samples was determined at Quintiles

Laboratories using a sandwich immunoassay. Human serum

samples and standards were incubated in microtiter plate wells

46

coated with a monoclonal anti-IL-6 antibody, in the presence of a second monoclonal anti IL-6 antibody, linked to acetylcholinesterase. After incubation, the wells were washed, and the bound enzymatic activity was measured using a chromogenic substrate. The intensity of the color was proportional to the concentration of IL-6 in the sample or standard. As shown by the AUC Figure 1, the average change in baseline for Interleukin-6 was lower in those subjects treated with ABT-627, demonstrating the effectivness of ABT-627 as an agent for reducing inflammation and ameliorating pain.

5

10

15

20

Bone Scan Methodology

Bone scans were performed with an NDA approved, Tc-99m phosphonate type radiopharmaceutical. This technique uses whole body format (skull to feet) so that anterior and posterior images are presented when using a 510 K-approved gamma camera. Alternatively, spot views covering both anterior and posterior projections of the total body can be obtained. Interpretation was performed according to standard nuclear medicine criteria, on a bone by bone basis, by recording the number of lesions at each site. Each site was evaluated against a confidence score of 1 to 5, where 1 is

47

negative, 2 is probably negative, 3 is equivocal, 4 is probably positive, and 5 is definitely positive. The MSKCC (Clin. Can. Res. 1998; 4:1765-1772) was used to record these findings. For the purposes of scoring the extent of disease or the response to treatment, lesions with a confidence score of 4 and 5 were considered positive, and all other lesions were considered negative. In addition, in a blinded study, a reference nuclear medicine physician interpreted the bone scans quantitatively as follows: the percent of involved bone was estimated for each individual bone, and the individual bone involvement was summed to calculate a global percent bone scan index (BSI). More specifically, the bone scan was separated into three indices. The first was the appindicular scan which involved arms and legs (i.e. the humorous and all bones distal to the humerous and the femur and everything distal to the femur). The second was the axial (everything but the arms and the legs). The results of these scans were combined to provide the total BSI.

10

15

Bone scans were conducted on each subject on day one of
the study, and on the final day of the study, and the
changes from baseline in bone scan index scores were analysed
by mean change and mean percent change, adjusting for baseline

48

characteristics as co-variates using SAS version XXX software.

As shown in Figure 6, bone scans indicated a decrease in the proportion of total skeketal involvement in those subjects receiving ABT-627 versus placebo, demonstrating the effectivness of ABT-627 as an agent for reducing the fraction of total skeletal involvement by tumor.

VAS Methodology/Administeration/Analysis

The Visual Analog Scale (VAS) is a common instrument of

pain assessment performed by having a subject draw a vertical

line on a 10 cm scale at the point that best describes his or

her pain on average in the last 24 hours. A diagram of the

scale is shown below:

No pain I-----I Pain as bad as it could possibly be

(not to scale)

During the course of the study, pain assessments were done daily, at bedtime, by the subject. If the subject was unable to maintain the log, a caregiver could complete the log on his or her behalf. The log also contained a table on which was recorded all daily pain medication consumed by the patient.

49

The logs of daily VAS scores and analgesic consumption were collected at biweekly visits of the subject to the clinic when a new log was distributed. Clinical personnel who received the logs measured the score by measuring the distance (in mm) from the "no pain" end mark to the point where the subject's line crossed the VAS line. The number was written into the case report form next to the date the subject completed that page of the logbook.

Subjects with pain were initially stabilized in their

pain so that their pain was treated to a tolerable and

constant level. For this study, "tolerable and constant"

refers to a pain score less than or equal to 5 cm on the VAS

for an average of seven successive days while using four or

less rescue doses of pain medication per day. A rescue

medication dose refers to a dose equal to one single dose a

patient used for common timed pain relief.

The weekly VAS scores were calculated excluding the lowest and highest score for each week and averaging the remaining five scores. If there were two days with the same VAS score, the day with the highest analgesic use was discarded.

20

The weekly mean VAS score was used to define subjects as

50

responders or non-responders. A subject was considered a responder based on the reduction in the pain intensity: a weekly VAS score reduction of greater than or equal to 25% during at least two consecutive weeks without an increase of analgesic use during the same period (compared to baseline). Alternatively, a subject was considered a responder if his pain analgesic consumption was reduced by at least 25% during at least two consecutive weeks without a concomitant increase in VAS score.

The percentage of responders in each treatment group was compared to evaluate drug efficacy. The comparison was subjected to an adjustment for baseline characteristics and prognostic factors as co-variates, and the analysis was performed using the Cochran-Mantel-Haenszel test or a generalized linear model.

10

15

20

Weekly VAS scores are examined using a longitudinal analysis method to explore trends over time. The duration of the response, defined as the time from baseline to the last weekly assessment for which the responder definition was satisfied, was analyzed using the Kaplan-Meier methodology and logrank test. Cox proportional hazard models were used as needed (see U.S. Department of Health and Human Services.

51

Management of Cancer Pain Clinical Practice Guidelines. AHCPR Publication #94-0592, Rockville, MD (1994). As shown by the AUC in Figure 3, VAS scores showed a decrease in pain, independent of the effects of morphine, after treatment with with ABT-627, demonstrating the effectivness of ABT-627 as an agent for ameliorating pain.

Osteoblastic Activity and Bone Markers

Markers of osteoblastic activity were assessed using urine samples. Bone markers include bone alkaline phosphatase (BAP), deoxypridinoline, and N-telopeptide of Type I collagen. Blood samples were collected prior to dosing on Day 1, Day 42, Day 84, Day 168, and every 28 days after Day 168, with a final collection on the last day of the study.

15

20

10

5

Bone Alkaline Phosphatase

Bone Alkaline Phosphatase levels were determined using the bone-specific Alkphase-B° assay published by Metra Biosystems (Mountain View, CA). As shown by the AUC in Figure 5, BAP levels decreased in subjects treated with ABT-627, demonstrating the effectivness of ABT-627 as an agent for inhibiting abnormal bone remodeling.

52

Crosslinked N-Telopeptide Levels:

Cross-linked N-telopeptide levels were determined using the DiaSorin (Stillwater, MN) assay for the quantitative determination of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in human serum by equilibrium radioimmunoassay (RIA). Briefly, samples were incubated with the 125 ICTP tracer and ICTP primary antibody for 2 hours at 37 °C. Following the 2 hour incubation, a pre-precipitated second antibody complex was added to separate the bound from free tracer. The assay was then centrifuged and decanted after a 30 minute incubation at room temperature. The bound tracer in the pellet was counted with a gamma counter. were inversely proportional to the amount of ICTP present in each sample. As shown by the AUC in Figure 4, Crosslinked Ntelopeptide levels decreased in subjects treated with ABT-627, demonstrating the effectivness of ABT-627 as an agent for inhibiting the bone remodeling associated with bone diseases.

10

53

We Claim:

- 1. A method for inhibiting bone metastases and metastatic growth in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.
- 2. The method of Claim 1 wherein the bone metastases are osteoblastic.

10

5

3. The method of Claim 2 wherein the osteoblastic bone metastases result from the spread of a primary cancer selected from breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.

- 4. The method of Claim 3 wherein the primary cancer is prostate cancer and the patient is male.
- 5. The method of Claim 1 which additionally comprises
 20 co-administeration of an anticancer drug.
 - 6. The method of Claim 5 wherein the anticancer drug

54

agent is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

5

- 7. The method of Claim 1 which additionally comprises the administeration of radiation therapy.
- 8. The method of Claim 1 which additionally comprises
 the administeration of at least one therapeutic agent which
 impedes net bone loss.
 - 9. The method of Claim 8 wherein the therapeutic agent is a bisphosphonate.

- 10. The method of Claim 1 wherein the endothelin antagonist is an $ET_{\mathtt{A}}$ -selective endothelin antagonist.
- 11. A method for the inhibition of bone loss in a

 20 patient which comprises administering to the patient in need
 thereof a therapeutically effective amount of an endothelin

 ET-A receptor antagonist.

- 12. The method of Claim 11 wherein the patient has cancer.
- 5 13. The method of Claim 11 wherein the cancer is prostate cancer and the patient is male.
- 14. The method of Claim 11 which additionally comprises the administeration of at least one therapeutic agent which impedes net bone loss.
 - 15. The method of Claim 14 wherein the therapeutic agent is a bisphosphonate.
- 16. A method for the reduction of cancer-related pain in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.
- 20 17. The method of Claim 16 wherein the cancer is prostate cancer and the patient is male.

56

- 18. The method of Claim 16 which additionally comprises the administeration of an anticancer drug.
- 19. The method of Claim 18 wherein the anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 10 20. The method of Claim 17 which additionally comprises the administeration of radiation therapy.
 - 21. A method for inhibiting bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula I:

$$R_2$$
 Z
 N
 R_3
 $CH_2)_n$
 R_1

I

wherein

15

R is $-(CH_2)_m-W$;

57

Z is selected from $-C(R_{18})(R_{19})$ - and -C(0) -;

R₁ and R₂ are independently selected from hydrogen,
loweralkyl, alkenyl, alkynyl, alkoxyalkyl,
alkoxyarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl,
5 alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl,
cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl,
dialkylaminocarbonylalkyl, aminocarbonylalkenyl,
alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl,
hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl,
10 arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl,
alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl,
and (R_{aa})(R_{bb})N-R_{CC}-,

with the proviso that one or both of R_1 and R_2 is other than hydrogen;

R3 is selected from R4-C(0)-R5-, R4-R5a-, R4-C(0)-R5-N(R6)-, R6-S(0)2-R7- R26-S(0)-R27-, R22-O-C(0)-R23-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and R13-C(0)-CH(R14)-;

 R_4 and R_6 are independently selected from $(R_{11})(R_{12})N_{-}$,

58

loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and

5

15

R₅ is selected from a covalent bond, alkylene, alkenylene, $-N(R_{20})-R_8-$, $-R_{8a}-N(R_{20})-R_8-$, $-O-R_9-$, and $-R_{9a}-O-R_9-$;

10 R₆ is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R7 is a covalent bond, alkylene, alkenylene $-N(R_{21})-R_{10}-$, and $-R_{10a}-N(R_{21})-R_{10}-$;

R8 is selected from alkylene and alkenylene;

R9 is alkylene;

R₁₀ is selected from alkylene and alkenylene;

 R_{11} and R_{12} are independently selected from hydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic,

WO 02/11713

5

15

arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl,trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, and carboxyalkyl;

R₁₃ is selected from amino, alkylamino and dialkylamino;

R₁₄ is selected from aryl and R₁₅-C(0)-;

R₁₅ is selected from amino, alkylamino and dialkylamino;

 R_{16} is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R₁₇ is loweralkyl;

10 R_{18} and R_{19} are independently selected from hydrogen and loweralkyl;

R20 is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cylcoalkyl and cycloalkylalkyl;

 $\ensuremath{\mathtt{R}}_{21}$ is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, aryl and arylalkyl;

R22 is selected from a carboxy protecting group and heterocyclic;

 R_{23} is selected from covalent bond, alkylene, alkenylene and $-N(R_{24})-R_{25}-;$

R24 is selected from hydrogen and loweralkyl;

60

R₂₅ is alkylene;

R26 is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxysubstituted haloalkyl;

R27 is selected from alkylene and alkenylene;
R5a is selected from alkylene and alkenylene;
R7a is alkylene;
R8a is selected from alkylene and alkenylene;

10 R9a is alkylene;

5

R_{10a} is selected from alkylene and alkenylene;

Raa is selected from aryl and arylalkyl;

R_{bb} is selected from hydrogen and alkanoyl;

R_{CC} is alkylene;

m is 0-6;

n is 0 or 1;

z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting

20 group; and

61

W is selected from $-C(O)_2-G$; $-PO_3H_2$, -P(O)(OH)(E), -CN, $-C(O)NHR_{17}$, alkylaminocarbonyl, dialkylaminocarbonyl, tetrazolyl, hydroxy, alkoxy, sulfonamido, $-C(O)NHS(O)_2R_{16}$, $-S(O)_2NHC(O)R_{16}$,

or a pharmaceutically acceptable salt thereof.

5

- 22. The method of Claim 21 wherein the bone metastases

 o are osteoblastic.
 - 23. The method of Claim 22 wherein the osteoblastic bone metastases result from the spread of a primary cancer selected from breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.
 - 24. The method of Claim 23 wherein the primary cancer is

62

prostate cancer and the patient is male.

25. The method of Claim 21 which additionally comprises the administeration of an anticancer drug.

5

- 26. The method of Claim 25 wherein the additional anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 27. The method of Claim 21 which additionally comprises the administeration of radiation therapy.

15

- 28. The method of Claim 21 which additionally comprises the administeration of at least one therapeutic agent which impedes net bone loss.
- 29. The method of Claim 28 wherein the therapeutic agent is a bisphosphonate.

63

30. A method for the inhibition of bone loss in cancer patients which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula I:

$$\begin{array}{c|c} R_2 & Z & R_3 \\ & & & \\ & & & \\ R_1 & & & \\ \end{array}$$

I

wherein

5

R is $-(CH_2)_m-W$;

Z is selected from $-C(R_{18})(R_{19})$ - and -C(0) -;

10 R₁ and R₂ are independently selected from hydrogen,
loweralkyl, alkenyl, alkynyl, alkoxyalkyl,
alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl,
alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl,
cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl,
15 dialkylaminocarbonylalkyl, aminocarbonylalkenyl,
alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl,
hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl,
arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl,
alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl,

64

and $(R_{aa})(R_{bb})N-R_{cc}$

with the proviso that one or both of \mathbf{R}_1 and \mathbf{R}_2 is other than hydrogen;

R3 is selected from R4-C(0)-R5-, R4-R5a-, R4-C(0)-R5
N(R6)-, R6-S(0)2-R7- R26-S(0)-R27-, R22-O-C(0)-R23-,

loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,

aryl, arylalkyl, aryloxyalkyl, heterocyclic,

(heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and R13-C(0)-CH(R14)-;

10 R4 and R6 are independently selected from (R11)(R12)N-, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and

R5 is selected from a covalent bond, alkylene, alkenylene, $-N(R_{20})-R_8-$, $-R_{8a}-N(R_{20})-R_8-$, $-O-R_9-$, and $-R_{9a}-O-R_9-$;

65

R6 is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

R7 is a covalent bond, alkylene, alkenylene -N(R21)-R10-, and -R10a-N(R21)-R10-;

R8 is selected from alkylene and alkenylene;
R9 is alkylene;

R₁₀ is selected from alkylene and alkenylene;

R₁₁ and R₁₂ are independently selected from hydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl,trialkylaminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, and carboxyalkyl;

 R_{13} is selected from amino, alkylamino and dialkylamino;

R₁₄ is selected from aryl and R₁₅-C(0)-;

R₁₅ is selected from amino, alkylamino and dialkylamino;

R₁₆ is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R₁₇ is loweralkyl;

10

15

R₁₈ and R₁₉ are independently selected from hydrogen and loweralkyl;

66

R20 is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cylcoalkyl and cycloalkylalkyl;

R₂₁ is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, aryl and arylalkyl;

 R_{22} is selected from a carboxy protecting group and heterocyclic;

 \mbox{R}_{23} is selected from covalent bond, alkylene, alkenylene and $-\mbox{N(R}_{24})-\mbox{R}_{25}-;$

10 R₂₄ is selected from hydrogen and loweralkyl;
R₂₅ is alkylene;

R26 is selected from loweralkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxysubstituted haloalkyl;

R27 is selected from alkylene and alkenylene;

 R_{5a} is selected from alkylene and alkenylene;

R_{7a} is alkylene;

R_{8a} is selected from alkylene and alkenylene;

20 R9a is alkylene;

15

R_{10a} is selected from alkylene and alkenylene;

67

Raa is selected from aryl and arylalkyl;

Rbb is selected from hydrogen and alkanoyl;

R_{CC} is alkylene;

m is 0-6;

5

15

n is 0 or 1;

z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from -C(O)₂-G; -PO₃H₂, -P(O)(OH)(E),

-CN, -C(O)NHR₁₇, alkylaminocarbonyl, dialkylaminocarbonyl,

tetrazolyl, hydroxy, alkoxy, sulfonamido, -C(O)NHS(O)₂R₁₆,
S(O)₂NHC(O)R₁₆,

or a pharmaceutically acceptable salt thereof.

68

31. The method of Claim 30 wherein the cancer is prostate cancer and the patient is male.

- 32. The method of Claim 30 which additionally comprises the administeration of at least one therapeutic agent which impedes net bone loss.
 - 33. The method of Claim 32 wherein the therapeutic agent is a bisphosphonate.

10

34. A method for the reduction of cancer-related pain which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:

$$\begin{array}{c|c}
R_2 & Z & R_3 \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\$$

Ι

15

wherein

R is
$$-(CH_2)_m-W$$
;

Z is selected from $-C(R_{18})(R_{19})$ and -C(0)-;

R₁ and R₂ are independently selected from hydrogen,

69

loweralkyl, alkenyl, alkynyl, alkoxyalkyl,
alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl,
alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl,
cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl,

5 dialkylaminocarbonylalkyl, aminocarbonylalkenyl,
alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl,
hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl,
arylalkoxyalkyl, (N-alkanoyl-N-alkyl)aminoalkyl,
alkylsulfonylamidoalkyl, heterocyclic, (heterocyclic)alkyl,

and (Raa) (Rbb) N-Rcc-,

with the proviso that one or both of \mathbf{R}_1 and \mathbf{R}_2 is other than hydrogen;

R₃ is selected from R₄-C(O)-R₅-, R₄-R_{5a}-, R₄-C(O)-R₅- $N(R_6)-, R_6-S(O)_2-R_7-R_{26}-S(O)-R_{27}-, R_{22}-O-C(O)-R_{23}-,$

loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, and R₁₃-C(O)-CH(R₁₄)-;

R4 and R6 are independently selected from $(R_{11})(R_{12})N$ -, loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl,

70

alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, and

R9 is alkylene;

R5 is selected from a covalent bond, alkylene, alkenylene, $-N(R_{20})-R_8-$, $-R_{8a}-N(R_{20})-R_8-$, $-O-R_9-$, and $-R_{9a}-O-R_9-$;

R6 is selected from loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl or arylalkyl;

10 R7 is a covalent bond, alkylene, alkenylene $-N(R_{21})-R_{10}-$, and $-R_{10a}-N(R_{21})-R_{10}-$;

R8 is selected from alkylene and alkenylene;

R₁₀ is selected from alkylene and alkenylene;

15 R₁₁ and R₁₂ are independently selected from hydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkylalkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, (heterocyclic)alkyl, hydroxyalkyl, alkoxy, aminoalkyl,trialkylaminoalkyl, alkylaminoalkyl,

71

dialkylaminoalkyl, and carboxyalkyl;

R13 is selected from amino, alkylamino and dialkylamino;

R₁₄ is selected from aryl and R₁₅-C(0)-;

R₁₅ is selected from amino, alkylamino and dialkylamino;

R₁₆ is selected from loweralkyl, haloalkyl, aryl and dialkylamino;

R₁₇ is loweralkyl;

5

15

 R_{18} and R_{19} are independently selected from hydrogen and loweralkyl;

10 R₂₀ is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, cylcoalkyl and cycloalkylalkyl;

R21 is selected from hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl and arylalkyl;

R22 is selected from a carboxy protecting group and heterocyclic;

 \mbox{R}_{23} is selected from covalent bond, alkylene, alkenylene and $-\mbox{N(R}_{24}) - \mbox{R}_{25} -;$

R24 is selected from hydrogen and loweralkyl;

20 R₂₅ is alkylene;

R26 is selected from loweralkyl, haloalkyl, alkenyl,

72

alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic)alkyl, alkoxyalkyl and alkoxysubstituted haloalkyl;

R27 is selected from alkylene and alkenylene;

R_{5a} is selected from alkylene and alkenylene;

R_{7a} is alkylene;

R_{8a} is selected from alkylene and alkenylene;

R9a is alkylene;

R_{10a} is selected from alkylene and alkenylene;

10 R_{aa} is selected from aryl and arylalkyl;

Rbb is selected from hydrogen and alkanoyl;

R_{CC} is alkylene;

m is 0-6;

n is 0 or 1;

15 z is 0-5;

E is selected from hydrogen, loweralkyl and arylalkyl;

G is selected from hydrogen and a carboxy protecting group; and

W is selected from $-C(O)_2-G$; $-PO_3H_2$, -P(O)(OH)(E),

20 -CN, -C(O)NHR17, alkylaminocarbonyl, dialkylaminocarbonyl,

73

tetrazolyl, hydroxy, alkoxy, sulfonamido, $-C(0)NHS(0)_2R_{16}$, $-S(0)_2NHC(0)R_{16}$,

or a pharmaceutically acceptable salt thereof.

- 35. The method of Claim 34 wherein the cancer is prostate cancer and the patient is male.
- 10 36. The method of Claim 34 which additionally comprises the administeration of an anticancer drug.
- 37. The method of Claim 36 wherein the additional anticancer drug is selected from leuprolide, goserelin,

 bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

74

38. A method for inhibiting bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula III

5

III.

- 39. The method of Claim 38 wherein the bone metastases are osteoblastic.
- 10 40. The method of Claim 39 wherein the osteoblastic bone metastases result from the spread of a primary cancer selected from breast, prostate, lung, kidney, thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and ovarian.
- 15 41. The method of Claim 40 wherein the primary cancer is

75

prostate cancer and the patient is male.

42. The method of Claim 40 which additionally comprises the administeration of an anticancer drug.

5

- 43. The method of Claim 42 wherein the additional anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 44. The method of Claim 40 which additionally comprises the administeration of radiation therapy.

15

10

- 45. The method of Claim 40 which additionally comprises the administeration of at least one therapeutic agent which impedes net bone loss.
- 20 46. The method of Claim 45 wherein the agent is a bisphosphonate.

76

47. The method of Claim 40 wherein the endothelin antagonist is an ${\rm ET}_{\rm A}\text{-selective}$ endothelin antagonist.

48. A method for the inhibition of bone loss in cancer patients which comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula III

III.

10

- 49. The method of Claim 48 wherein the cancer is prostate cancer and the patient is male.
- 50. The method of Claim 48 which additionally comprises the administeration of at least one therapeutic agent which

77

impedes net bone loss.

51. The method of Claim 50 wherein therapeutic agent is a bisphosphonate.

5

52. A method for the reduction of cancer-related pain which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula III

III.

10

53. The method of Claim 52 wherein the cancer is prostate cancer and the patient is male.

15

54. The method of Claim 52 which additionally

78


comprises the administeration of an anticancer drug.

- 55. The method of Claim 54 wherein the anticancer drug is selected from leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 56. A method for preventing new bone metastases in a


 10 patient which comprises administring to the patient in need
 thereof a therapeutically effective amount of an endothelin


 ET-A receptor antagonist.
- 57. A method for inhibiting metastatic growth in a


 patient which comprises administring to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.
- 58. A method for inhibiting bone turnover in a patient
 which comprises administring to the patient in need thereof a
 therapeutically effective amount of an endothelin ET-A
 receptor antagonist.




SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)







FIG. 6



<u>ب</u>

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 14 February 2002 (14.02.2002)

PCT

(10) International Publication Number WO 02/011713 A3

- (51) International Patent Classification⁷: A61K 31/40, 31/445, A61P 19/08
- (21) International Application Number: PCT/US01/24716
- **(22) International Filing Date:** 6 August 2001 (06.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/633,389 7 August 2000 (07.08.2000) US
- (71) Applicant: ABBOTT LABORATORIES [US/US]; D377 AP6D, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).
- (72) Inventors: JANUS, Todd, J.; 270 Big Terra Lane, Gurnee, IL 60031 (US). PADLEY, Robert, J.; 770 Moffett Road, Lake Bluff, IL 60044 (US).
- (74) Agents: STEELE, Gregory, W. et al.; Abbott Laboratories, 100 Abbott Park Road, D377 AP6D/2, Abbott Park, IL 60064-6050 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 17 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



011713 A

(54) Title: METHODS OF TREATING BONE CANCER AND THE PAIN ASSOCIATED THEREWITH USING ENDOTHELIN ANTAGONISTS

INTERNATIONAL SEARCH REPORT

. In: Inal Application No PCT/US 01/24716

a. classification of subject matter IPC 7 A61K31/40 A61K31/445 A61P019/08 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category 9 1-10, γ WO 00 36918 A (MARINE POLYMERS 21-29, TECHNOLOGIES I) 29 June 2000 (2000-06-29) 38-47,56 page 4, line 28 -page 5, line 2 page 29, line 27 -page 30, line 23 page 38, line 3 - line 14 NELSON J B ET AL: "NEW BONE FORMATION IN Х 1-10,56AN OSTEOBLASTIC TUMOR MODEL IS INCREASED BY ENDOTHELIN-1 OVEREXPRESSION AND DECREASED BY ENDOTHELIN A RECEPTOR **BLOCKADE**" UROLOGY, BELLE MEAD, NJ, US, vol. 53, no. 5, May 1999 (1999-05), pages 1063-1069, XP001037666 ISSN: 0090-4295 page 1063, column 1 Υ 21-29, 38-47,56 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. ° Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the International filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 2 6. 02. 2003 25 February 2003 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016 Bonzano, C

INTERNATIONAL SEARCH REPORT

Int onal Application No PCT/US 01/24716

0.40	V. A PAGUNTATA AGNORADES TO DE ESTADOS	PC1/03 01/24/10
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	In
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YIN J J ET AL: "Osteoblastic bone metastases: Tumor-produced endothelin-1 mediates new bone formation via the endothelin A receptor." CANCER, vol. 88, no. 12, 15 June 2000 (2000-06-15), pages 3093-3094, XP008009105 Second North American Symposium on Skeletal Complications of Malignancy; Montreal, Canada; October 15-16, 1999 ISSN: 0008-543X page 3094, column 1, line 31 - line 43	1-10, 21-29, 38-47,56
P,X	WO 01 00198 A (CALIFORNIA INST OF TECHN) 4 January 2001 (2001-01-04) page 6, line 13 - line 30 claims 1,5,8,9	1,21,38, 56
Α	LAHAV R ET AL: "AN ENDOTHELIN RECEPTOR B ANTAGONIST INHIBITS GROWTH AND INDUCES CELL DEATH IN HUMAN MELANOMA CELLS IN VITRO AND IN VIVO" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 20, September 1999 (1999-09), pages 11496-11500, XP001026099 ISSN: 0027-8424	
X	WO 97 30045 A (ABBOTT LAB) 21 August 1997 (1997-08-21) page 626, line 17 - line 28 page 1	1-10, 21-29, 38-47,56
A	WO 99 06397 A (ABBOTT LAB) 11 February 1999 (1999-02-11) cited in the application claims 1,62,70,71	

International application No. PCT/US 01/24716

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 1-10,21-29,38-47,56 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1, 5-10 (all partially), 2-4, 21-29, 38-47, 56
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-10,56 relate to a compound defined by reference to a desirable characteristic or property, namely the activity as endothelin ET-A receptor antagonist.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to its pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Present claims 21-29 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables and possible permutations that a lack of conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Consequently, the search for the first invention has been carried out for those parts of the claims which appear to be clear and concise, supported and disclosed, namely those parts relating to the compound mentioned in the example, and in claim 38, with due regard to the general idea underlying the present invention.

Claims searched completely: 38-47. Claims searched incompletely: 1-10,21-29,56

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int mal Application No
PCT/US 01/24716

				161703	01/24/10
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0036918		29-06-2000	US AU CA CN EP NO WO	6063911 A 2591900 A 2356087 A1 1335749 T 1139752 A1 20013071 A 0036918 A1	16-05-2000 12-07-2000 29-06-2000 13-02-2002 10-10-2001 20-08-2001 29-06-2000
WO 0100198	A	04-01-2001	AU EP WO	6065000 A 1280552 A2 0100198 A2	31-01-2001 05-02-2003 04-01-2001
WO 9730045	А	21-08-1997	AU BR CN CZ EP JP NZ WO US US HU	2262097 A 9707509 A 1384100 A 1219172 A ,B 9802537 A3 0885215 A1 2002504081 T 330818 A 9730045 A1 6462194 B1 6380241 B1 6162927 A 9901580 A2	02-09-1997 27-07-1999 11-12-2002 09-06-1999 14-07-1999 23-12-1998 05-02-2002 26-05-2000 21-08-1997 08-10-2002 30-04-2002 19-12-2000 28-09-2000
WO 9906397	A	11-02-1999	USU AUU BG BRN EPU PO NZ PK TR TRO US	6162927 A 748469 B2 8592198 A 104216 A 9815296 A 1301264 T 1003740 A2 0003484 A2 2001512119 T 20000542 A 502395 A 342500 A1 1452000 A3 200000993 T2 200101233 T2 200101234 T2 9906397 A2 6462194 B1	19-12-2000 06-06-2002 22-02-1999 29-12-2000 20-11-2001 27-06-2001 31-05-2000 28-01-2002 21-08-2001 04-04-2000 28-08-2002 04-06-2001 10-05-2001 21-12-2000 21-06-2002 21-06-2002 11-02-1999 08-10-2002